Emergent Biosolutions EBS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $156.1M-29.7% | $148.7M-23.6% | $231.1M-21.3% | $140.9M-44.7% | $222.2M-26.0% | ||
| $72M-18.6% | $84.9M-28.1% | $85.9M-29.9% | $66.9M-77.4% | $88.5M-38.8% | ||
| $84.1M-37.1% | $63.8M-16.8% | $145.2M-15.2% | $74M+279% | $133.7M-14.2% | ||
| 53.9%-6.3pp | 42.9%+3.5pp | 62.8%+4.6pp | 52.5%+68.8pp | 60.2%+8.3pp | ||
| $10.5M-30.5% | $12.1M+33.0% | $13.5M-2.2% | $12.5M-61.8% | $15.1M0.0% | ||
| $46.6M-11.1% | $51.1M-16.0% | $38.9M-49.2% | $43.7M-49.1% | $52.4M-38.1% | ||
| $16.5M+1.2% | $16.3M0.0% | $16.3M0.0% | $16.2M-0.6% | $16.3M+0.6% | ||
| $145.6M-15.5% | $176.6M-13.5% | $154.6M-32.6% | $139.3M-69.6% | $172.3M-33.9% | ||
| $10.5M-79.0% | —— | $76.5M+18.6% | $1.6M+101% | $49.9M+25.4% | ||
| 6.7%-15.7pp | —— | 33.1%+11.1pp | 1.1%+81.0pp | 22.5%+9.2pp | ||
| $11M-25.2% | $14.7M-0.7% | $15.2M+83.1% | $14.7M-37.7% | $14.7M-39.5% | ||
| $2.9M-93.2% | -$22.8M-26.0% | -$18.9M-124% | -$18.4M+72.2% | $42.8M+255% | ||
| $0+100% | $12.2M— | $0-100% | $0+100% | -$12.2M— | ||
| $13.4M-85.5% | —— | $57.6M-59.6% | -$16.8M+93.8% | $92.7M+666% | ||
| $6.6M-73.3% | $3.9M+5.4% | $6.4M-76.8% | -$4.8M-136% | $24.7M+697% | ||
| $6.8M-90.0% | —— | $51.2M-55.4% | -$12M+95.8% | $68M+656% | ||
| 4.4%-26.2pp | —— | 22.2%-16.9pp | -8.5%+103pp | 30.6%+27.6pp | ||
| $0.07-94.1% | —— | $0.91-55.8% | -$0.22+95.9% | $1.19+600% | ||
| $0.13-89.6% | —— | $0.96-55.6% | -$0.22+95.9% | $1.25+635% | ||
| 56.5M-1.4% | 56.7M+7.0% | 56.5M+1.6% | 54.2M+3.0% | 57.3M+9.8% | ||
| 51.9M-4.6% | 53.5M+0.9% | 53.2M+0.2% | 54.2M+3.0% | 54.4M+4.2% | ||
| $16.5M+1.2% | $16.3M0.0% | $16.3M0.0% | $16.2M-0.6% | $16.3M+0.6% | ||
| $0+100% | —— | —— | $0+100% | -$12.2M— | ||
| $13.9M-80.1% | —— | -$3.7M-117% | -$3.7M-37.0% | $69.7M+2,150% | ||
| $156.1M-29.7% | $148.7M-23.6% | $231.1M-21.3% | $140.9M-44.7% | $222.2M-26.0% | ||
| $10.5M-79.0% | —— | $76.5M+18.6% | $1.6M+101% | $49.9M+25.4% | ||
| $34M-54.8% | —— | $99.9M+9.9% | $25.1M+114% | $75.3M+11.2% | ||
| $34M-54.8% | —— | $99.9M+9.9% | $25.1M+114% | $75.3M+11.2% | ||
| 21.8%-12.1pp | —— | 43.2%+12.3pp | 17.8%+86.5pp | 33.9%+11.4pp | ||
| $10.5M-79.0% | —— | $76.5M+18.6% | $1.6M+101% | $49.9M+25.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Emergent Biosolutions's revenue?
- Emergent Biosolutions (EBS) generated $676.8M in revenue over the trailing twelve months, down 29.9% year over year.
- Is Emergent Biosolutions profitable?
- Emergent Biosolutions reported $114.0M in net income over the trailing twelve months, a 9.6% net margin.
- What are Emergent Biosolutions's profit margins?
- Gross margin is 54.2% and operating margin is 15.0%, with a 9.6% net margin.
- What is Emergent Biosolutions's earnings per share?
- Emergent Biosolutions's diluted EPS over the trailing twelve months is $1.95.
- Where does Emergent Biosolutions's income statement data come from?
- Every line is extracted from Emergent Biosolutions's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
